{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "16767370",
  "DateCompleted": {
    "Year": "2006",
    "Month": "11",
    "Day": "09"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "11",
    "Day": "13"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1436-3291",
      "JournalIssue": {
        "Volume": "9",
        "Issue": "2",
        "PubDate": {
          "Year": "2006"
        }
      },
      "Title": "Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association",
      "ISOAbbreviation": "Gastric Cancer"
    },
    "ArticleTitle": "Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy.",
    "Pagination": {
      "StartPage": "136",
      "EndPage": "139",
      "MedlinePgn": "136-9"
    },
    "Abstract": {
      "AbstractText": [
        "Single-agent or combined chemotherapy with the novel oral fluoropyrimidine anticancer drug, S-1 (TS-1), has been reported to be useful for the treatment of advanced gastric cancer. Here, we report a patient with advanced gastric cancer achieving a complete response (CR) after 2 weeks of administration of S-1 as neoadjuvant chemotherapy. A 78-year-old woman with epigastric pain was diagnosed as having advanced gastric cancer. S-1 was administered orally, at a dose of 50 mg twice a day every day for 2 weeks, followed by a 2-week drug-free period. No obvious adverse reactions occurred. Subsequently, the patient underwent distal partial gastrectomy with D2 lymph node dissection. Pathological examination indicated no remnant signet-ring cells in the excised specimen, no lymph node metastasis, and unnatural fibrosis in one of the No. 3 lymph nodes. The neoadjuvant chemotherapy induced a CR according to the Japanese classification of gastric carcinoma."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Surgery, Aizawa Hospital, 2-5-1 Honjou, Matsumoto, Nagano 390-8510, Japan."
          }
        ],
        "LastName": "Mori",
        "ForeName": "Shusuke",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kishimoto",
        "ForeName": "Hirofumi",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Tauchi",
        "ForeName": "Katsunori",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Higuchi",
        "ForeName": "Kayoko",
        "Initials": "K"
      }
    ],
    "PublicationTypeList": [
      "Case Reports",
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Japan",
    "MedlineTA": "Gastric Cancer",
    "NlmUniqueID": "100886238",
    "ISSNLinking": "1436-3291"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antimetabolites, Antineoplastic"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Drug Combinations"
    },
    {
      "RegistryNumber": "150863-82-4",
      "NameOfSubstance": "S 1 (combination)"
    },
    {
      "RegistryNumber": "1548R74NSZ",
      "NameOfSubstance": "Tegafur"
    },
    {
      "RegistryNumber": "5VT6420TIG",
      "NameOfSubstance": "Oxonic Acid"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antimetabolites, Antineoplastic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Chemotherapy, Adjuvant"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Combinations"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Gastrectomy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Neoadjuvant Therapy"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Oxonic Acid"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prognosis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Remission Induction"
    },
    {
      "QualifierName": [
        "drug therapy",
        "pathology",
        "surgery"
      ],
      "DescriptorName": "Stomach Neoplasms"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Tegafur"
    }
  ]
}